Trans-splicing mediated photodynamic therapy

Details Trans-splicing mediated photodynamic therapy Trans-splicing mediated photodynamic therapy

2008-07-15

2008-07-15

Guzo, David (Department: 1636)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S325000, C435S455000, C435S069100, C435S091100, C435S091300

Reexamination Certificate

active

07399753

ABSTRACT:
The present invention provides methods and compositions for conferring selective death on cells expressing a specific target precursor messenger RNA (selective target pre-mRNA). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) expressed within a cell and mediate a trans-splicing reaction resulting in the generation of a novel chimeric mRNA molecule (chimeric mRNA) capable of encoding a light producing protein or enzyme. Cell death is further mediated by the presence of a photosensitizer which upon photoactivation produces cytotoxicity.

REFERENCES:
patent: 2004/0038403 (2004-02-01), Otto
patent: 2004/0058344 (2004-03-01), Mitchell et al.
Liu et al., Nature Biotechnology, Jan. 2002, vol. 20, pp. 47-52.
Puttaraju et al., Nature Biotechnology, 1999, vol. 17, pp. 246-252.

Affiliated with

Also associated with

Rating

Trans-splicing mediated photodynamic therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Trans-splicing mediated photodynamic therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trans-splicing mediated photodynamic therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2811877